Cargando…

Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies

Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavletic, ZS, Joshi, SS, Pirruccello, SJ, Tarantolo, SR, Kollath, J, Reed, EC, Bierman, PJ, Vose, JM, Warkentin, PI, Gross, TG, Nasrati, K, Armitage, JO, Kessinger, A, Bishop, MR
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101861/
https://www.ncbi.nlm.nih.gov/pubmed/9486492
http://dx.doi.org/10.1038/sj.bmt.1701037
_version_ 1783511709770579968
author Pavletic, ZS
Joshi, SS
Pirruccello, SJ
Tarantolo, SR
Kollath, J
Reed, EC
Bierman, PJ
Vose, JM
Warkentin, PI
Gross, TG
Nasrati, K
Armitage, JO
Kessinger, A
Bishop, MR
author_facet Pavletic, ZS
Joshi, SS
Pirruccello, SJ
Tarantolo, SR
Kollath, J
Reed, EC
Bierman, PJ
Vose, JM
Warkentin, PI
Gross, TG
Nasrati, K
Armitage, JO
Kessinger, A
Bishop, MR
author_sort Pavletic, ZS
collection PubMed
description Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ⩾500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8(+) ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8(+) cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting.
format Online
Article
Text
id pubmed-7101861
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-71018612020-03-31 Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies Pavletic, ZS Joshi, SS Pirruccello, SJ Tarantolo, SR Kollath, J Reed, EC Bierman, PJ Vose, JM Warkentin, PI Gross, TG Nasrati, K Armitage, JO Kessinger, A Bishop, MR Bone Marrow Transplant Article Forty-one patients were studied at set times after allogeneic blood stem cell transplantation (alloBSCT) for recovery of lymphocyte numbers and function. Cells were mobilized with G-CSF from HLA-matched related donors and cryopreserved. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate; G-CSF was administered post-transplant. Median time to absolute lymphocyte count (ALC) ⩾500/μl was 17 days vs 41 and 49 days in historical alloBMT patients with G-CSF (n = 23) or no cytokine (n = 29) post-transplant, respectively (P < 0.0001). CD4/CD8(+) ratio was 1.9 on day 28 after alloBSCT, then gradually declined to 0.8 at 1 year due to more rapid CD8(+) cell recovery. Mean phytohemagglutinin-induced T cell responses were lower than normal on day +28 (P < 0.05), then tended to recover towards normal values. Natural-killer cytotoxicity remained low from day +28 to 1 year post-alloBSCT, but considerable lymphokine-activated killer cytotoxicity was induced from cells already obtained on day +28. Faster lymphocyte recovery correlated with better survival in alloBSCT patients (median follow-up 287 days, P = 0.002), ALC recovery was not affected by acute GVHD, CMV infections or doses of infused cells. ALC recovery did not correlate with survival in either historical alloBMT group. These data suggest that after alloBSCT lymphocyte reconstitution is faster than after alloBMT, and that quicker lymphocyte recovery predicts better survival in the alloBSCT setting. Nature Publishing Group UK 1998-02-13 1998 /pmc/articles/PMC7101861/ /pubmed/9486492 http://dx.doi.org/10.1038/sj.bmt.1701037 Text en © Macmillan Publishers Limited 1998 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Pavletic, ZS
Joshi, SS
Pirruccello, SJ
Tarantolo, SR
Kollath, J
Reed, EC
Bierman, PJ
Vose, JM
Warkentin, PI
Gross, TG
Nasrati, K
Armitage, JO
Kessinger, A
Bishop, MR
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
title Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
title_full Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
title_fullStr Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
title_full_unstemmed Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
title_short Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
title_sort lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101861/
https://www.ncbi.nlm.nih.gov/pubmed/9486492
http://dx.doi.org/10.1038/sj.bmt.1701037
work_keys_str_mv AT pavleticzs lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT joshiss lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT pirruccellosj lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT tarantolosr lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT kollathj lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT reedec lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT biermanpj lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT vosejm lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT warkentinpi lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT grosstg lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT nasratik lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT armitagejo lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT kessingera lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies
AT bishopmr lymphocytereconstitutionafterallogeneicbloodstemcelltransplantationforhematologicmalignancies